focus -WSS

focus

author：hotspot 2025-09-30 17:45:18 - browse：75

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Traditional Chinese medicine benefits explored in new JAMA study

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Traditional Chinese medicine benefits explored in new JAMA study

Ultragenyx gene therapy for rare liver ailment succeeds in late

Biden's order seeks to regulate AI risk without stifling innovation

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Intellia reports positive results for its CRISPR

explore

focus

focus

In Memoriam: Notable people who died in 2023

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Moonlake's readout produced a cash windfall. Risks remain

Telehealth options flood the market as retailers push virtual care

Anesthesiologist group: stop taking Ozempic before surgery

Traditional Chinese medicine benefits explored in new JAMA study

Continuity nursing helped my family in our darkest PICU moments

Cassava reveals details — and problems — with Alzheimer's study

hotspot

See how much Covid

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Maker of FluMist seeks to allow at

Physician subsidies by hospitals soar in wake of No Surprises Act

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Paying for Covid pills will soon shift to insurers

entertainment

Wikipedia

Wikipedia

focus